• Langley Road, Brighton, MA
  • 416-402-8274

NIH Licensing Opportunity: A Novel Highly Effective HIV Vaccine: Made More Effective Due to a Multi-Component Approach to Preventing and Treating HIV Infection




This webinar already occurred on December 16, 2020 but a recording can be watched below:

Signature Square OMSIH logo

NIH Licensing Opportunity: Improving Efficacy of HIV Vaccines

One Million Solutions in Health™ has established a one-of-a-kind partnership with the United States’ National Institutes of Health Office of Technology Transfer (NIH-OTT) and the National Cancer Institute Technology Transfer Center (NCI-TTC) to increase awareness and understanding of NIH technologies by potential partners in the life science and healthcare industries.

This provides you with a front-row seat to hear about new technology and science from various scientists at the NIH. This is also your opportunity to participate in our proprietary Signature Square™ process, where end-users can evaluate the technology, ask questions and provide feedback directly to the scientist.
Increasing HIV Vaccine Efficacy

This webinar will incorporate three technologies that work independently, but when combined, result in a higher level of HIV vaccine efficacy:

The first technology (E-160-2018), is a V1 region deleted gp120 modified protein, that shows an increased immune response to the V2 region and superior vaccine efficacy.

The second technology (E-062-2014), demonstrates that increasing RAS activation results in increased vaccine efficacy. The thought here is to combine a RAS activation agent with the first technology’s V1 region deleted gp120 modified protein (E-160-2018) to further enhance the vaccine’s effectiveness.

The third technology (E-154-2000), demonstrates how a recombinant DNA and an ALVAC vector can be used to manufacture a more potent vaccine candidate. The thought here is to use this method to manufacture the V1 region deleted gp120 modified protein, to further enhance the effectiveness of the resulting V1 deleted gp120 vaccine.

This is an opportunity to LICENSE TECHNOLOGIES E-160-2018, E-062-2014 and/or E-154-2000, or collaborate with the NCI to commercialize these technologies.

The Signature Square process is part of our Consortium infrastructure. Current member companies in the Technology Evaluation Consortium and SafeTEC include organizations like AstraZeneca, AbbVie, Amgen and Allergan, along with many others, including scientists, clinicians and investors in organizations around the world who help to evaluate this technology.

This is your opportunity to ask questions and provide feedback directly to the scientists by taking part in this Signature Square program.

Genoveffa Franchini, M.D.
Senior Investigator
Vaccine Branch
Head, Animal Models and Retroviral Vaccines Section
Dawn Van Dam
Executive Director & CEO
One Million Solutions in Health™